Tigecycline : the use in an universitary hospital may lead to better outcomes?
Visualizar/abrir
Data
2018Autor
Orientador
Co-orientador
Nível acadêmico
Graduação
Assunto
Abstract
Objectives: The aim of this study was to asses the use of tigecycline in differents therapeutic schemes in an universitary hospital. Methods: A retrospective study was conducted, including data (prontuary review) of patients who used tigecycline at a tertiary teaching hospital from January/2015 to March/2018. Patients were divided into two groups: group “standard dose”, with patients using 100 mg as attack dose, followed by 50 mg of tigecycline every 12 hours; and group “high dose”, including p ...
Objectives: The aim of this study was to asses the use of tigecycline in differents therapeutic schemes in an universitary hospital. Methods: A retrospective study was conducted, including data (prontuary review) of patients who used tigecycline at a tertiary teaching hospital from January/2015 to March/2018. Patients were divided into two groups: group “standard dose”, with patients using 100 mg as attack dose, followed by 50 mg of tigecycline every 12 hours; and group “high dose”, including patients who used 200 mg, followed by 100 mg every 12 hours. Results: 43 patients received high doses and 44, standard doses of tigecycline. The main etiological agents were Klebsiella pneumoniae (87%), which were recovered from different body sites. Overall in-hospital mortality was 55.2%, with no significant difference between groups (p > 0.05). Also, there was no difference between survival time (p > 0.05). Conclusion: Among patients enrolled in this study, there was no statistically significant difference in mortality between the two groups. Heterogeneity of types of infections is our major limitation. More studies are necessary to definitively elucidate influence of high dose’s based schemes in each particular type of infections. ...
Instituição
Universidade Federal do Rio Grande do Sul. Faculdade de Farmácia. Curso de Farmácia.
Coleções
-
TCC Farmácia (676)
Este item está licenciado na Creative Commons License
![](/themes/Mirage2Novo//images/lume/cc.png)